Compare CYCU & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYCU | CDIO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 74 | 17 |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.4M |
| IPO Year | N/A | N/A |
| Metric | CYCU | CDIO |
|---|---|---|
| Price | $0.53 | $1.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 492.8K | 33.3K |
| Earning Date | 06-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.92 | $171,906.75 |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.97 |
| 52 Week High | $7.13 | $7.91 |
| Indicator | CYCU | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 42.31 |
| Support Level | $0.23 | $1.68 |
| Resistance Level | $1.05 | $2.16 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 41.62 | 18.18 |
Cycurion Inc. provides information technology security solutions through its subsidiaries. The company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company has one reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.